Rituximab vs cyclophosphamide for cancer risk in ANCA-associated vasculitis

Journal Article Accepted manuscript Rituximab vs cyclophosphamide for cancer risk in ANCA-associated vasculitis Get access Arjun Mahajan, Arjun Mahajan Harvard Medical School, Boston, MA, USADivision of Rheumatology, Inflammation, and Immunity, Brigham & Women's Hospital, Boston, MA, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Martin Viola, Martin Viola Harvard Medical School, Boston, MA, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Jacob Ellen, Jacob Ellen Harvard Medical School, Boston, MA, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Evan W Piette, Evan W Piette Harvard Medical School, Boston, MA, USADepartment of Dermatology, Brigham and Women's Hospital, Boston, MA, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Avery H LaChance, Avery H LaChance Harvard Medical School, Boston, MA, USADepartment of Dermatology, Brigham and Women's Hospital, Boston, MA, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Jeffrey A Sparks Jeffrey A Sparks Harvard Medical School, Boston, MA, USADivision of Rheumatology, Inflammation, and Immunity, Brigham & Women's Hospital, Boston, MA, USA Corresponding author details: Jeffrey A. Sparks MD, MPH, 60 Fenwood Road, Boston, MA 02115, USA, [email protected] Search for other works by this author on: Oxford Academic PubMed Google Scholar Rheumatology, keaf167, https://doi.org/10.1093/rheumatology/keaf167 Published: 24 March 2025 Article history Received: 17 March 2025 Accepted: 18 March 2025 Published: 24 March 2025